OKYO
OKYO Pharma Limited
Price Chart
Latest Quote
$1.57
-0.02 (-1.26%)
Current Price
| Previous Close | $1.59 |
| Open | $1.57 |
| Day High | $1.60 |
| Day Low | $1.54 |
| Volume | 53,773 |
Stock Information
| Shares Outstanding | 52.48M |
| Total Debt | $186K |
| Cash Equivalents | $4.22M |
| Net Income | $-4.61M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $82.39M |
| EPS (TTM) | $-0.11 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $56.34M |
| Income | $-4.61M |
| Book/sh | $-0.09 |
| Cash/sh | $0.08 |
| Employees | 4 |
Financial Ratios
| Quick Ratio | 0.53 |
| Current Ratio | 0.58 |
Returns & Margins
| ROA | -104.63% |
Ownership
| Insider Ownership | 30.41% |
| Institutional Ownership | 20.81% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -7.85 |
| P/B | -17.64 |
Analyst Data
| Recommendation | none |
| Target Price | $9.00 |
Technical Indicators
| SMA20 | $1.61 |
| SMA50 | $1.61 |
| SMA200 | $1.94 |
| RSI | 35.42 |
| ATR | 0.0954 |
| Shares Float | 20.55M |
| Short Float | 0.29% |
| Short Ratio | 2.50 |
| Volatility | 0.02 |
| Rel Volume | 0.88 |
Performance History
| Week | +3.29% |
| Month | -1.87% |
| Quarter | +0.00% |
| 6 Months | -14.21% |
| YTD | -29.60% |
| Year | -30.22% |
| 3 Years | +21.71% |
| 10 Years | -56.63% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $1.57 | 53,800 |
| 2026-06-18 | $1.59 | 65,100 |
| 2026-06-17 | $1.57 | 75,500 |
| 2026-06-16 | $1.50 | 47,500 |
| 2026-06-15 | $1.52 | 79,800 |
| 2026-06-12 | $1.52 | 157,100 |
| 2026-06-11 | $1.55 | 54,900 |
| 2026-06-10 | $1.49 | 76,700 |
| 2026-06-09 | $1.54 | 41,300 |
| 2026-06-08 | $1.59 | 22,800 |
| 2026-06-05 | $1.62 | 70,100 |
| 2026-06-04 | $1.68 | 58,600 |
| 2026-06-03 | $1.66 | 31,600 |
| 2026-06-02 | $1.70 | 54,100 |
| 2026-06-01 | $1.71 | 46,600 |
| 2026-05-29 | $1.72 | 27,400 |
| 2026-05-28 | $1.71 | 54,200 |
| 2026-05-27 | $1.69 | 25,600 |
| 2026-05-26 | $1.71 | 125,400 |
About OKYO Pharma Limited
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
đ° Latest News
OKYO Pharma expands scientific advisory board with cornea expert - ICYMI
Proactive âĸ 2026-05-23T12:00:00Z
What Makes OKYO Pharma (OKYO) a New Buy Stock
Zacks âĸ 2026-05-20T16:00:03Z
OKYO Pharma Strengthens Scientific Advisory Board With Marta Sacchetti Appointment
Proactive âĸ 2026-05-19T15:02:22Z
OKYO Pharma adds ophthalmology specialist Marta Sacchetti to Scientific Advisory Board
Proactive âĸ 2026-05-19T13:58:00Z
OKYO Pharma to hold Scientific Advisory Board meeting at ASCRS 2026
Proactive âĸ 2026-04-07T12:40:00Z
OKYO Pharma reports improved quality-of-life outcomes in mid-stage eye pain trial
Proactive âĸ 2026-03-18T13:02:00Z
Dow Jones sheds more than 800 points on Trump's latest tariff threat
Proactive âĸ 2026-02-23T21:15:00Z
OKYO Pharma to present first-in-human urcosimod data at ARVO 2026
Proactive âĸ 2026-02-23T16:56:00Z
Nasdaq posts slim gain in calm trade as Wall Street inches up
Proactive âĸ 2026-02-17T21:20:00Z
OKYO Pharma has analysts bullish as FDA endorses Phase 2b/3 trial in neuropathic corneal pain
Proactive âĸ 2026-02-17T17:56:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $870,279 | $1,053,313 | $96,687 | $0 |
| Total Expenses | $7,091,897 | $15,749,732 | $13,187,200 | $6,217,566 |
| Net Non Operating Interest Income Expense | $-878,174 | $-1,053,313 | $-96,687 | $0 |
| Total Other Finance Cost | $13,368 | - | - | - |
| Interest Expense Non Operating | $870,279 | $1,053,313 | $96,687 | $0 |
| Operating Expense | $7,091,897 | $15,749,732 | $13,187,200 | $6,217,566 |
| Other Operating Expenses | $4,837,653 | $7,506,161 | $6,849,502 | $4,608,008 |
| Other Income Expense | - | - | - | - |
| General And Administrative Expense | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-4,706,292 | $-16,825,461 | $-13,271,685 | $-5,431,045 |
| Net Interest Income | $-878,174 | $-1,053,313 | $-96,687 | $0 |
| Interest Income | $5,473 | $0 | $0 | $0 |
| Normalized Income | $-4,706,292 | $-16,825,461 | $-13,271,685 | $-5,431,045 |
| Net Income From Continuing And Discontinued Operation | $-4,706,292 | $-16,825,461 | $-13,271,685 | $-5,431,045 |
| Net Income Common Stockholders | $-4,706,292 | $-16,825,461 | $-13,271,685 | $-5,431,045 |
| Net Income | $-4,706,292 | $-16,825,461 | $-13,271,685 | $-5,431,045 |
| Net Income Including Noncontrolling Interests | $-4,706,292 | $-16,825,461 | $-13,271,685 | $-5,431,045 |
| Net Income Continuous Operations | $-4,706,292 | $-16,825,461 | $-13,271,685 | $-5,431,045 |
| Pretax Income | $-7,970,071 | $-16,803,045 | $-13,283,887 | $-6,217,566 |
| Interest Income Non Operating | $5,473 | $0 | $0 | $0 |
| Operating Income | $-7,091,897 | $-15,749,732 | $-13,187,200 | $-6,217,566 |
| Special Income Charges | - | - | $0 | $0 |
| Total Operating Income As Reported | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-0.12 | $-0.57 | $-0.61 | $-0.36 |
| Basic EPS | $-0.12 | $-0.57 | $-0.61 | $-0.36 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-7,097,229 | $-15,745,866 | $-13,183,403 | $-6,215,235 |
| Reconciled Depreciation | $2,563 | $3,866 | $3,797 | $2,331 |
| EBITDA (Bullshit earnings) | $-7,097,229 | $-15,745,866 | $-13,183,403 | $-6,215,235 |
| EBIT | $-7,099,792 | $-15,749,732 | $-13,187,200 | $-6,217,566 |
| Diluted Average Shares | $39,488,256 | $29,343,727 | $22,257,058 | $798,259,356 |
| Basic Average Shares | $39,488,256 | $29,343,727 | $22,257,058 | $15,064,813 |
| Diluted NI Availto Com Stockholders | $-4,706,292 | $-16,825,461 | $-13,271,685 | $-5,431,045 |
| Tax Provision | $-3,263,779 | $22,416 | $-12,202 | $-786,521 |
| Research And Development | $2,254,244 | $8,243,571 | $6,337,698 | $1,609,558 |
| Total Unusual Items | - | - | $0 | $0 |
| Total Unusual Items Excluding Goodwill | - | - | $0 | $0 |
| Write Off | - | - | $0 | $0 |
| Otherunder Preferred Stock Dividend | - | - | - | - |
| Impairment Of Capital Assets | - | - | - | - |
| Selling General And Administration | - | - | - | - |
| Salaries And Wages | - | - | - | - |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-5,549,555 | $-5,879,582 | $-2,053,237 | $2,947,402 |
| Total Assets | $3,677,336 | $1,541,264 | $5,203,920 | $4,300,593 |
| Total Non Current Assets | $2,035 | $3,350 | $7,216 | $5,225 |
| Current Assets | $3,675,301 | $1,537,914 | $5,196,704 | $4,295,368 |
| Prepaid Assets | $225,360 | $130,126 | $171,248 | $711,209 |
| Receivables | $1,889,039 | $580,940 | $980,075 | $883,435 |
| Other Receivables | $4,500 | $5,585 | $340,848 | $19,130 |
| Taxes Receivable | $1,884,539 | $575,355 | $639,227 | $864,305 |
| Cash Cash Equivalents And Short Term Investments | $1,560,902 | $826,848 | $4,045,381 | $2,700,724 |
| Cash And Cash Equivalents | $1,560,902 | $826,848 | $4,045,381 | $2,700,724 |
| Cash Financial | $1,560,902 | $826,848 | $4,045,381 | $2,700,724 |
| Other Current Assets | - | - | - | - |
| Debt | ||||
| Total Debt | - | - | $2,215,111 | $0 |
| Current Debt And Capital Lease Obligation | - | - | $2,215,111 | - |
| Current Debt | - | - | $2,215,111 | - |
| Other Current Borrowings | - | - | $2,215,111 | - |
| Long Term Debt And Capital Lease Obligation | - | - | - | $0 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $9,226,891 | $7,420,846 | $7,257,157 | $1,353,191 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $9,226,891 | $7,420,846 | $7,257,157 | $1,353,191 |
| Payables And Accrued Expenses | $9,226,891 | $7,420,846 | $5,042,046 | $1,353,191 |
| Payables | $8,848,310 | $6,590,671 | $3,166,969 | $788,848 |
| Other Payable | $88,999 | $103,830 | $73,197 | - |
| Accounts Payable | $7,899,986 | $6,128,132 | $2,314,581 | $741,807 |
| Equity | ||||
| Common Stock Equity | $-5,549,555 | $-5,879,582 | $-2,053,237 | $2,947,402 |
| Total Equity Gross Minority Interest | $-5,549,555 | $-5,879,582 | $-2,053,237 | $2,947,402 |
| Stockholders Equity | $-5,549,555 | $-5,879,582 | $-2,053,237 | $2,947,402 |
| Other Equity Interest | $2,228,563 | $4,842,358 | $3,711,132 | $2,408,453 |
| Gains Losses Not Affecting Retained Earnings | $-11,470,420 | $-11,311,447 | $-11,452,542 | $-11,011,527 |
| Retained Earnings | $-143,024,972 | $-142,523,180 | $-125,697,719 | $-112,426,034 |
| Other | ||||
| Ordinary Shares Number | $36,020,815 | $33,336,316 | $51,039,764 | $21,144,853 |
| Share Issued | $36,020,815 | $33,336,316 | $51,039,764 | $21,144,853 |
| Tangible Book Value | $-5,549,555 | $-5,879,582 | $-2,053,237 | $2,947,402 |
| Invested Capital | $-5,549,555 | $-5,879,582 | $161,874 | $2,947,402 |
| Working Capital | $-5,551,590 | $-5,882,932 | $-2,060,453 | $2,942,177 |
| Total Capitalization | $-5,549,555 | $-5,879,582 | $-2,053,237 | $2,947,402 |
| Foreign Currency Translation Adjustments | $-11,470,420 | $-11,311,447 | $-11,452,542 | $-11,011,527 |
| Capital Stock | $146,717,274 | $143,112,687 | $131,385,892 | $123,976,510 |
| Common Stock | $146,717,274 | $143,112,687 | $131,385,892 | $123,976,510 |
| Current Accrued Expenses | $378,581 | $830,175 | $1,875,077 | $564,343 |
| Dueto Related Parties Current | $859,325 | $358,709 | $779,191 | $47,041 |
| Net PPE | $2,035 | $3,350 | $7,216 | $5,225 |
| Accumulated Depreciation | $-8,465 | $-7,117 | $-8,099 | $-4,554 |
| Gross PPE | $10,500 | $10,467 | $15,315 | $9,779 |
| Machinery Furniture Equipment | $10,500 | $10,467 | $15,315 | $9,779 |
| Capital Lease Obligations | - | - | - | $0 |
| Long Term Capital Lease Obligation | - | - | - | $0 |
| Current Capital Lease Obligation | - | - | - | $0 |
| Properties | - | - | - | $0 |
| Duefrom Related Parties Current | - | - | - | $0 |
| Additional Paid In Capital | - | - | - | - |
| Leases | - | - | - | - |
| Buildings And Improvements | - | - | - | - |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-1,812,139 | $-9,490,537 | $-7,701,158 | $-5,469,734 |
| Operating Activities | ||||
| Operating Cash Flow | $-1,810,931 | $-9,490,537 | $-7,695,242 | $-5,468,065 |
| Cash Flow From Continuing Operating Activities | $-1,810,931 | $-9,490,537 | $-7,695,242 | $-5,468,065 |
| Operating Gains Losses | $-191,262 | $53,764 | $38,780 | $-28,558 |
| Investing Activities | ||||
| Capital Expenditure | $-1,208 | - | $-5,916 | $-1,669 |
| Investing Cash Flow | $-1,208 | $0 | $-5,916 | $-1,669 |
| Cash Flow From Continuing Investing Activities | $-1,208 | $0 | $-5,916 | $-1,669 |
| Net Other Investing Changes | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $1,705,742 | $6,208,508 | $7,323,354 | $0 |
| Financing Cash Flow | $2,655,742 | $6,208,508 | $9,323,354 | $2,153,270 |
| Cash Flow From Continuing Financing Activities | $2,655,742 | $6,208,508 | $9,323,354 | $2,153,270 |
| Net Common Stock Issuance | $1,705,742 | $6,208,508 | $7,323,354 | $0 |
| Common Stock Issuance | $1,705,742 | $6,208,508 | $7,323,354 | $0 |
| Net Other Financing Charges | - | - | - | - |
| Other | ||||
| Issuance Of Debt | $950,000 | $0 | $2,000,000 | $0 |
| End Cash Position | $1,560,902 | $826,848 | $4,045,381 | $2,700,724 |
| Beginning Cash Position | $826,848 | $4,045,381 | $2,700,724 | $6,889,329 |
| Effect Of Exchange Rate Changes | $-109,549 | $63,496 | $-277,539 | $-872,141 |
| Changes In Cash | $843,603 | $-3,282,029 | $1,622,196 | $-3,316,464 |
| Net Issuance Payments Of Debt | $950,000 | $0 | $2,000,000 | $0 |
| Net Short Term Debt Issuance | $950,000 | $0 | $2,000,000 | $0 |
| Short Term Debt Issuance | $950,000 | $0 | $2,000,000 | $0 |
| Net PPE Purchase And Sale | $-1,208 | $0 | $-5,916 | $-1,669 |
| Purchase Of PPE | $-1,208 | $0 | $-5,916 | $-1,669 |
| Taxes Refund Paid | $1,998,364 | $0 | $199,153 | $0 |
| Change In Working Capital | $1,626,644 | $2,669,464 | $3,945,796 | $-1,023,869 |
| Change In Other Current Assets | $-90,403 | $440,257 | $167,718 | $-802,154 |
| Change In Payables And Accrued Expense | $1,717,047 | $2,229,207 | $3,778,078 | $-249,091 |
| Change In Payable | $1,717,047 | $2,229,207 | $3,778,078 | $-249,091 |
| Change In Account Payable | $1,216,431 | $2,799,282 | $2,963,759 | $-297,991 |
| Other Non Cash Items | $1,987,842 | $3,464,141 | $114,991 | $61,721 |
| Stock Based Compensation | $734,989 | $1,121,273 | $1,286,128 | $1,737,876 |
| Depreciation Amortization Depletion | $2,563 | $3,866 | $3,797 | $2,331 |
| Depreciation And Amortization | $2,563 | $3,866 | $3,797 | $2,331 |
| Depreciation | $2,563 | $3,866 | $3,797 | $2,331 |
| Gain Loss On Investment Securities | $-94,284 | $-1,419 | $-12,412 | $-19,149 |
| Net Foreign Currency Exchange Gain Loss | $-96,978 | $55,183 | $51,192 | $-9,230 |
| Net Income From Continuing Operations | $-7,970,071 | $-16,803,045 | $-13,283,887 | $-6,217,566 |
| Proceeds From Stock Option Exercised | - | $0 | $0 | $2,153,270 |
| Net Long Term Debt Issuance | - | $0 | $0 | $0 |
| Long Term Debt Issuance | - | $0 | $0 | $0 |
| Change In Receivables | - | $0 | $167,718 | $27,376 |
| Gain Loss On Sale Of PPE | - | $0 | $0 | $-179 |
| Repayment Of Debt | - | - | $0 | $0 |
| Long Term Debt Payments | - | - | $0 | $0 |
| Asset Impairment Charge | - | - | $0 | $0 |
| Changes In Account Receivables | - | - | - | $27,376 |
Fetched: 2026-06-23